Xtandi benefit larger in certain TNBC patients

Data from a Phase II trial of Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) and Medivation Inc. (NASDAQ:MDVN) to treat triple-negative breast cancer (TNBC) showed a stronger clinical benefit in patients where gene profiling showed an androgen-driven gene signature than in patients without the signature. The data were released in an abstract published ahead of the American Society for Clinical Oncology meeting.

The data showed a 16-week clinical benefit rate of 39% in androgen signature patients (95% CI: 27, 53) and 11% in non-signature patients (95% CI: 5, 21). At 24 weeks, the CBR was 36% in androgen signature patients (95% CI: 24, 49) and 7% in non-signature patients (95% CI: 2, 16). ...